GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » 3-Year Revenue Growth Rate
Switch to:

Biogen (BUE:BIIB) 3-Year Revenue Growth Rate

: -3.20% (As of Dec. 2022)
View and export this data going back to 2019. Start your Free Trial

Biogen's Revenue per Share for the three months ended in Dec. 2022 was ARS2,933.30.

During the past 12 months, Biogen's average Revenue per Share Growth Rate was -5.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -3.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Biogen was 157.10% per year. The lowest was -32.50% per year. And the median was 18.80% per year.


Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen 3-Year Revenue Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Biogen's 3-Year Revenue Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 3-Year Revenue Growth Rate's extreme value range as defined by GuruFocus.



Biogen 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Biogen  (BUE:BIIB) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Biogen 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Biogen's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines